Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Gracell Biotechnologies
company
About
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $100M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$185M
Gracell Biotechnologies has raised a total of
$185M
in funding over 2 rounds. Their latest funding was raised on
Oct 28, 2020 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 28, 2020 | Series C | $100M | 2 | — | — | Detail |
| Feb 25, 2019 | Series B | $85M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Gracell Biotechnologies is funded by 3 investors.
King Star Capital
and Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
Lilly Asia Ventures
|
— | Series C |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
